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Abstract Microglial cells are resident macrophages in the
brain and their activation is an important part of the brain
immune response and the pathology of the major CNS
diseases. Microglial activation is triggered by pathological
signals and is characterized by morphological changes,
proliferation, phagocytosis and the secretion of various
cytokines and inflammatory mediators, which could be both
destructive and protective for the nervous tissue. Purines
are one of the most important mediators which regulate
different aspects of microglial function. They could be
released to the extracellular space from neurons, astrocytes
and from the microglia itself, upon physiological neuronal
activity and in response to pathological stimuli and cellular
damage. Microglial activation is regulated by various
subtypes of nucleotide (P2X, P2Y) and adenosine (A1,
A2A and A3) receptors, which control ionic conductances,
membrane potential, gene transcription, the production of
inflammatory mediators and cell survival. Among them, the
role of P2X7 receptors is especially well delineated, but
P2X4,v a r i o u sP 2 Y ,A 1,A 2A and A3 receptors also
powerfully participate in the microglial response. The
pathological role of microglial purine receptors has also
been demonstrated in disease models; e.g., in ischemia,
sclerosis multiplex and neuropathic pain. Due to their
upregulation and selective activation under pathological
conditions, they provide new avenues in the treatment of
neurodegenerative and neuroinflammatory illnesses.
Key words adenosinereceptors.ATP.microglia.
neurodegeneration.P2X7 receptor.P2Yreceptors
Abbreviations
AD Alzheimer’s disease
Aβ amyloid-β peptide
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Introduction
Microglial cells originate from monocyte/macrophage pre-
cursors and are regarded as the major immunocompetent cell
typeofthe nervous system, constitutingabout 10% ofall cells
in the brain. The immune response of the brain is spatially
segregated from the peripheral immune response by the blood
brain barrier and together with astroglial cells and infiltrating
peripheral immune cells, is predominantly executed by
microglial cells. Thus, this cell type is rapidly activated in
response to pathological signals such as ischemia or bacterial
endotoxin and respond with morphological changes trans-
forming the resting ramified microglia to an amoeboid form
with phagocytic activity, proliferation and the production of a
wide array of inflammatory mediators. Although microglial
activationisahighlycomplexprocess,consistingofanumber
of interrelated extra- and intracellular pathways, it is a rather
uniform response, which is triggered by any environmental
challenge,whichaffectsthefunctionalintegrityofthenervous
tissue. Therefore, microglial activation is heavily implicated
in the pathogenesis of virtually all CNS diseases and the
following repair process, including brain and spinal cord
injury, stroke, Alzheimer’s (AD) and Parkinson’sd i s e a s e
(PD), sclerosis multiplex (SM), amyotrophic lateral sclerosis
(ALS) and sensory neuropathies. Apart from cytokines,
growth factors, and other bioactive substances, purines are
one of the most important mediators which regulate and
orchestrate various aspects of microglial activation by the
interaction of numerous subtypes of adenosine (P1) and
nucleotide (P2) receptors.
Purine bioavailability under conditions leading
to microglial activation
The participation of purines in the microglial response
presumes their accumulation in the extracellular space upon
signals activating microglia. Extracellular purine availabil-
ity in the nervous system is basically determined by the
balance of release, and removal by enzymatic degradation
and uptake. Whereas ATP is released per se, adenosine is
thought to be generated in the extracellular space as a
breakdown product of released ATP, but it could be also
released on its own right, depending on the type of
stimulus. Since ATP is ubiquitous, all metabolically active
cells of the nervous system are able to synthesize ATP,
which provides a potential pool for release. Therefore, the
cellular source of released purines participating in micro-
glial activation could be any cell type located in contact
with microglia, i.e., nerve terminals, astrocytes, endothelial
tissue and finally the microglial cells themselves as well.
The majority of ATP is formed in the mitochondria by
oxidative phosphorylation, which results in approximately
10 mM ATP concentration in the cytoplasm under normal
metabolic conditions. In addition, ATP is also taken up and
stored in synaptic vesicles of nerve terminals [1] and
astrocytes [2]. On the other hand, the basal intracellular
adenosine concentration is much less, in the low micromo-
lar to high nanomolar range, and the majority of adenosine,
which is taken up into cells is rapidly reincorporated into
ATP stores, or deaminated by adenosine deaminase under
normal metabolic conditions [3].
A wide variety of stimuli are known to release ATP and/
or adenosine to the extracellular space, which theoretically
could lead to purine levels sufficiently high to activate
nucleotide receptors expressed on the surface of microglia
(Fig. 1)[ 1, 3, 4]. Although the stimulation-dependent
release of ATP and adenosine upon conventional [5, 6] and
high frequency [7] neuronal activity is well documented,
these stimuli probably result in a spatially restricted,
localized increase in extracellular purine levels, which
serve the synaptic transmission and the modulation of pre-
and postsynaptic functions within the synaptic cleft. ATP-
metabolizing ectoenzymes, present on the nerve terminal
membrane, but also on the surface of microglia [8], such as
ectoNTPDases, the CD73/ecto-5′-nucleotidase [9]a n d
nucleoside transporters may strongly limit purine availabil-
ity under these conditions. On the other hand, pathological
events such as mechanical or metabolic stress, inflamma-
tion, cellular injury or changes in the ionic environment are
known also to powerfully stimulate purine release. This
might result in a purine-rich extracellular milieu leading to
a more widespread activation of receptors reaching also the
neighboring or distant cells such as astrocytes and micro-
glia as well. These signals include mechanical [2, 10, 11]
and hypotonic [12] stimuli, hypoxia/hypoglycemia/ische-
mia and consequent energy deprivation [13–17], inflam-
matory signals, such as bacterial lypopolisaccharide (LPS)
[18, 19], concanavalin-A [20], or interleukin-1β (IL–1β)
[21], and cytolysis, which could release purines not only
from neurons but also from non-neuronal cells, i.e., from
astrocytes, endothelial cells and from the microglia itself.
Moreover, nucleotides and nucleosides by themselves may
promote further release ofp u r i n e s ,b yah o m o -o r
heteroexchange mechanism, if they reach relatively high
concentration in the extracellular space [22].
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Fig. 1 A summary of purinergic pathways involved in microglial
response. Since ATP is ubiquitous, it is present in the cytoplasm of
nerve terminals, astrocytes, and the microglia itself. It is released to
the extracellular space in response to a wide variety of signals,
including neuronal firing, mechanical stimuli, ischemia/energy depri-
vation, bacterial endotoxin and cellular damage. Adenosine could be
either released from cells, or generated from extracellular ATP via
breakdown by NTPDase (NTPD) and CD73/5′-nucleotidase (CD73)
enzymes. The action of adenosine is terminated by its uptake into
nerve terminals by the equilibrative nucleoside transporter system
(ENT), and the same transporters could mediate the release of adeno-
sine under energy deprivation. ATP acts on ionotropic P2X7 and P2X4
receptors, and also on metabotopic P2Y receptors, whereas adenosine
activates metabotropic A1,A 2A and A3 receptors, all present on the
surface of activated microglia. Whilst the activation of P2X receptors
triggers an inward cationic current and depolarizes the microglial
membrane, the activation of P2Y receptors is coupled to the G protein-
phospholipase C (PLC) signal transduction pathway, both resulting in
the elevation of intracellular Ca
2+. P2X receptors are involved in the
expression, posttranslational processing and secretion of various
factors shaping the microglial response—i.e., IL–1β,I L –6, IL–18,
TNF-α, reactive oxygen intermediates (ROI), plasminogen, 2-arach-
ydonoyl glycerate (2-AG), and microglial response factor−1( MRF-1)
—and thereby contribute to both the proinflammatory and antiin-
flammatory aspects of microglial activation. In addition, P2X7 re-
ceptors eventually also mediate apoptosis by caspase 1 activation. The
stimulation of P2Y receptors hyperpolarizes the microglia, via an
outward K
+ conductance and inhibits the production of proinflamma-
tory mediators. Adenosine receptors regulate the proliferation/survival
of microglia, COX-2 expression and subsequent secretion of PGF2,
and the production of nerve growth factor (NGF). For more details
and references, see text. For the sake of clarity, details of intracellular
signal transduction and transcriptional changes are not illustrated
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pass freely through the cell membrane, it is also of interest
to identify the mechanism, whereby it could enter the
extracellular space. These include (1) vesicular exocytosis,
(2) carrier-mediated release, (3) release through channels
and membrane pores, (4) cytolytic release.
(1) Vesicular exocytosis is a prototype mechanism for
neurotransmitters to enter the extracellular space,
which is expected to be a [Ca
2+]o-dependent process.
Indeed, [Ca
2+]o-dependent ATP and adenosine release
in response to neuronal stimulation appears in many
areas of the central and peripheral nervous system (for
further references see [1, 3, 4]. Moreover, recent
findings indicate that vesicular ATP release could be
derived not only from nerve terminals but also from
astrocytes [2].
(2) Although specific transporters capable for the trans-
membrane movement of ATP are yet to be molecu-
larly identified in the nervous system, ABC (ATP
binding cassette) proteins have been implicated as
ATP transporters [12, 23, 24] in non-neuronal cells.
These transporters are also expressed in glial cells [25]
and mediate ATP release upon hypoosmotic challenge
[26, 27]. On the other hand, transmembrane trans-
porters for adenosine and other nucleosides are widely
expressed in the nervous system. Specific nucleoside
transporters consist of two families: equilibrative
transporters (ENT) and concentrative transporters
(CNT); the former is driven by the concentration
gradient, the latter is driven by the sodium gradient
[28, 29]. ENT transporters could carry different
nucleosides, including adenosine and inosine, but not
nucleotides, across the cell membrane in both direc-
tions, and they are regarded as the dominant nucleo-
side transporters of the brain. Since the intracellular
adenosine level under normal metabolic state is in the
low micromolar range [3], if the ENT transporter is
loaded from the extracellular space by excess adeno-
sine, it mediates adenosine uptake into the nerve
terminals. When adenosine is taken up, intracellular
adenosine eliminating mechanisms, the adenosine
kinase and adenosine deaminase enzymes convert it
to AMP and inosine, respectively, thereby maintaining
the driving force of the carrier. However, the ENT
transporter could also act in a reverse direction under
certain circumstances, mediating the release of aden-
osine into the extracellular space. This could occur
during energy deprivation or metabolic distress, when
ATP stores are depleted and AMP is generated
intracellularly. Cytosolic 5′-nucleotidase, which has a
relatively high Km for AMP (1–14 μM), becomes
active under these conditions and accumulates aden-
osine intracellularly. This adenosine then flows out to
the extracellular space in a transporter-mediated
manner [3, 30].
(3) Channels and pores are also potential candidates to
drive the transmembrane movement of ATP. Connexin
hemichannels are gap junction proteins, and their main
function is to mediate electrical signaling, but they are
also able to release neuroactive substances such as
glutamate and ATP [31]. They have been recently
identified to mediate ATP release from astrocytes and
other non-neuronal cells in response to mechanical
stress [32–35].
(4) Although it has only recently received direct
experimental proof [36], any kind of cellular injury
is generally thought to result in high local ATP
concentrations in the extracellular space. In this case
the millimolar cytoplasmic ATP is expected to flow
out to the extracellular space through the membrane
damage.
Apart from release, the other major factor determining
purine bioavailability is their removal from the extracellular
space by enzymatic degradation and transporters. Several
enzyme families are responsible for the extracellular degra-
dation of ATP in the nervous system. The first step of the
inactivation of ATP is mediated by the family of ectonucleo-
side triphosphate diphospho-hydrolases (E-NTPDases, EC
3.6.1.5, also known as ectoATPase or apyrase), which are
able to hydrolyse ATP and ADP to AMP [9]. These enzymes
show widespread distribution in the brain [37, 38] and have
low micromolar Km for ATP and ADP giving rise to rapid
and highly effective hydrolysis of ATP in almost all neuronal
tissues. In addition to the E-NTPDase family, ATP could also
be dephosphorylated by ecto-nucleotide pyrophosphatases
(E-NPPs) and by alkaline phosphatases, both having
broader substrate specificity, but also widespread tissue
distribution [9].
The next step of extracellular inactivation is the
hydrolysis of AMP by the ecto-5′-nucleotidase (EC
3.1.3.5) enzyme, which is the rate-limiting step giving rise
to the formation of adenosine, which is a new extracellular
signal, acting on its own receptors. Ecto-5′-nucleotidase
exhibits micromolar Km for AMP and is feed-forwardly
inhibited by ATP, which results in a delayed, ‘burst-like’
adenosine production [30]. It is also widely present in the
brain, and it is predominantly associated to glial cells [39,
40], although its expression has been also demonstrated in
purified nerve terminals [41, 42]. Finally, adenosine,
generated by the ecto-5′-nucleotidase, or released on its
own right, is then taken up to the nerve terminal by specific
nucleoside transporters (see above) and rapidly reincorpo-
rated to ATP stores, or deaminated extra- or intracellularly
by the adenosine deaminase enzyme.
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It has been known for a considerable time that microglial
cells respond with both ionotropic and metabotropic
actions to ATP application [43–47]. Whereas the activa-
tion of ligand-gated P2X receptors produces depolariza-
tion and Ca
2+ influx through the receptor-ion channel
complex, the stimulation of the G protein coupled P2Y
receptors elicits hyperpolarization via phospholipase C
(PLC)- and IP3-mediated mobilization of Ca
2+ from
intracellular stores and subsequent opening of K
+ channels
(Fig. 1)[ 47]. Now it is confirmed that all members of the
P2 receptor family are expressed on resting and activated
microglial cells kept in culture at the mRNA and/or
protein level [48, 49].
Among various subtypes of the ionotropic P2 receptors,
the role of P2X7 receptors in the microglial response is
especially well delineated. Within the P2X receptor family,
the P2X7 receptor has a distinguished role for several
reasons. First, this receptor seems to function only in homo-
oligomeric form, and is activated by relatively high
concentrations of ATP. Second, this receptor was also
known previously as P2z receptor, the ‘cell death receptor’;
its prolonged activation elicits the opening of a transmem-
brane pore, permeable to large molecular weight molecules
up to 800 Da, which finally leads to cellular death. Last but
not least, in spite of being cloned originally from the rat
brain, it was suggested that P2X7 receptors are expressed
predominantly on antigen-presenting immune cells and
epithelia, and function as immunomodulatory receptors
[50, 51]. Supporting this concept, a wealth of data confirm
that P2X7 receptors regulate many aspects of immune
response in the periphery [52], but this holds true for
microglial activation as well [53].
The presence of the ‘pore-forming’ ATP receptor on
microglial cells has already been described before the
molecular identification of P2X7 receptors [54, 55]. The
expression of P2X7 receptor transcripts and of the cor-
responding protein have been confirmed later in both
cultured microglial cells [51, 56, 57] and in situ microglial
cells activated following middle cerebral artery occlusion
[51].
Primary microglial cultures and immortalized microglial
cell lines respond to ATP and 2′,3′-O-(4-benzoyl-benzoyl)
adenosine 5′-triphosphate (BzATP) application with an
inward current [54, 58, 59], membrane depolarization, a
sustained increase in intracellular free Ca
2+ [55], the uptake
of high molecular weight fluorescent dyes [55, 58], and the
secretion of IL–1β upon an LPS stimulus [55, 60, 61], with
a pharmacological profile resembling that of P2X7 recep-
tors. The central role of P2X7 receptors, as co-stimulators of
the posttranslational processing of IL–1β in microglial cells
upon LPS challenge has been repeatedly proven [19, 61,
62]. The mechanism underlying ATP dependent IL–1β
maturation and release in this cell type involves an
outwardly directed K
+ conductance and the activation of
interleukin-1 convertase enzyme (ICE, also known as
caspase 1) responsible for the cleavage of pro-IL1β to the
mature, 17-kDa form [61]. This mechanism appears to
participate not only in the exogenous but also in the
endogenous activation of P2X7 receptors, since LPS
releases ATP from microglial cells, and the P2X7 receptor
selective antagonist oxiATP prevents the LPS-induced IL–
1β release [19].
Interestingly, ADP and AMP also act as agonists of
P2X7 receptors in microglial cells in terms of membrane
currents and LPS induced IL–1β secretion, but only after
‘priming’ of the cells by ATP challenge [63]. The molecular
mechanism underlying the priming effect of ATP could be a
reversible conformational change leading to the modifica-
tion of the agonist binding motif, or the gating properties of
the P2X7 receptor, or its activity-dependent phosphoryla-
tion. This priming effect, on the other hand, does not extend
to the pore-forming property of recombinant and microglial
P2X7 receptors [63].
In addition to IL–1β, the synthesis and release of other
cytokines, are also stimulated by P2X7 receptor activation
in the microglia. Hence, ATP is a full stimulus (i.e., without
the requirement of priming by LPS) to induce TNFα
production via a Ca
2+-dependent, extracellular signal
regulated protein kinase (ERK)/JNK/p38 signaling path-
way [64, 65], although P2 receptors other than P2X7 may
also participate in ATP-induced ERK activation [65]. On
the other hand, involvement of P2X7 receptors in the
regulation of the production of the antiinflammatory
cytokine, interleukin-6 (IL–6) is more controversial.
Whereas Inoue et al. [66, 67] reported that ATP-induced
IL–6 production is not mediated by P2X7 receptors, a
recent study found markedly elevated levels of IL–6 in the
inflamed hindpaw of P2X
 = 
7 mice [68], implicating the
participation of this receptor in shaping IL–6 levels.
Moreover, Rampe et al. [69] reported that P2X7 receptors
play a role in the distinct modulation of cytokine secretory
pathways not only after LPS, but also upon amyloid beta
peptide (Aβ) pre-activation. Whereas the production of IL–
1β,I L –1α, TNFα and IL–18 was increased, that of IL–6,
the anti-inflammatory cytokine was attenuated under these
conditions, implicating the involvement of P2X7 receptors
in the pathogenesis of Alzheimer’s disease [69].
High concentrations of ATP induce inducible nitric oxide
synthase (iNOS) mRNA expression and increase nitric
oxide (NO) production from rat microglia [70], an effect
potentially mediated by P2X7 receptors. In contrast, ATP by
itself does not induce iNOS expression, but enhances IFNγ-
induced iNOS expression and subsequent NO production in
the murine BV-2 microglial cell line through an ERK1/2
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BzATP also promote the generation of reactive oxygen
intermediates (ROI), in particular superoxide, by interacting
with P2X7 receptors, in a way depending on extracellular
Ca
2+ and the p38 mitogen activated protein kinase (MAPK)
pathway [71]. The stimulation of P2X7 receptors elicits a
pronounced increase in the secretion of the endocannabi-
noid, 2-arachydonoylglycerate (2-AG) in primary micro-
glial cell cultures by the activation of diacylglycerol lipase
and the simultaneous inhibition of monoacylycerol lipase,
the enzyme responsible for endocannabinoid degradation
[72]. This mechanism is noteworthy, because endocannabi-
noids are also recognized as key regulators of microglial
activation [73]. Finally, activation of P2X7 receptors by low
concentration of agonists stimulates the release of the
neuroprotective mediator plasminogen from cultured micro-
glia [74]. Therefore, regulation of the production of
putatively protective (plasminogen, TNFα,2 - A G )a n d
harmful (IL–1β, NO) mediators by P2X7 receptors appears
to follow a highly time- and concentration-dependent
pattern [67].
In addition to its role to regulate the production of
inflammatory mediators, the activation of P2X7 receptors
elicits changes in microglia at the transcriptional level; it
rapidly activates the transcription factor nuclear factor of
activated T cells (NFAT) in a [Ca
2+]o-dependent manner
[75] as well as causes the nuclear translocation of NF-κB
via ROIs and caspase activation leading to the transcription
of a subset of NF-κB target genes [76]. The expression of
other transcription factors is regulated time-dependently
upon P2X7 receptor activation. While an acute exposition
(10 min to 1 h) of microglial cells to ATP and BzATP
upregulates the production of the inflammation related
protein microglial response factor (MRF)-1 [77], long-term
(6 h) exposure suppresses its transcription and synthesis
[78]. Moreover, a conditioned medium from cerebellar
granule cells undergoing apoptosis also upregulated MRF-1
release in a P2X7 receptor-mediated manner, indicating that
this mechanism plays a role in the neuron-microglia cross-
talk during microglial activation in response to apoptotic
signals [78].
According to its pore-forming property, the sustained
activation of P2X7 receptors leads to cytolysis in an
apoptotic fashion in the microglia [57]. The P2X7 recep-
tor-mediated apoptosis involves the activation of the
proteolytic pathway of the caspase activation, which leads
to nuclear DNA damage, but is not an absolute requirement
for the membrane damage and cytolysis; i.e., if caspases are
inhibited, cell death proceeds through the necrotic pathway
[79]. Nevertheless, the P2X7 receptor activated IL–1β
secretion and cell death, although both processes involve
caspases and both are eliminated in P2X
 = 
7 mice, appear to
be independent from each other [62].
Finally, P2X7 receptor activation also plays an important
role in Ca
2+ signaling between astrocytes and microglial
cells [11]. Astrocyte populations coordinate their functions
via Ca
2+ waves, and the spread of the Ca
2+ signal is
implemented by two ways: an intercellular pathway
mediated by gap junctions, and an extracellular pathway
mediated by ATP and P2 receptors [80]. Moreover,
astrocytes communicate by calcium-mediated signaling
not only with each other but also with neighboring cells,
including neurons and microglia. Thus, astrocyte-derived
ATP activates P2X7 receptors on microglial cells and elicits
Ca
2+ signals in the microglia, a process which eventually
leads to cytolysis of this cell type [11]. It is interesting to
note that P2X7 receptor-activation in astrocytes usually
does not lead to cytolysis, whilst the same effect might
cause cellular death in microglia. The reason for the
different resistance of astrocytes and microglia against the
P2X7 receptor mediated cytolysis is unknown.
The widespread and profound effects of P2X7 receptor
activation on different aspects of microglial activation
implicates the role of these receptors in the pathology of
CNS and PNS diseases and provokes their applicability as
therapeutic targets. Indeed, rapidly emerging knowledge
supports such a role, in particular the demonstration of (1)
the activity-dependent expression of P2X7 receptors under
pathological conditions, and (2) the protective role of P2X7
receptor ligands in animal disease models. The diseases, in
which microglial P2X7 receptors may play either a harmful
or protective function include neurodegenerative and neuro-
inflammatory diseases, such as ischemia-reperfusion and
traumatic injury, Alzheimer’s disease, sclerosis multiplex,
neuro- and retinopathies. In fact, the upregulation of
microglial P2X7 receptors has been observed in several
pathological models, including in vivo ischemia [81], a
transgenic model of Alzheimer’s disease [71], as well as in
human tissue samples obtained from patients suffering in
proliferative vitreoretinopathy [82], and sensory nerve
injury [68].
The first study showing an upregulation of P2X7
receptors in the brain was that of Collo et al. [51], who
found an increased immunostaining for P2X7 receptors in
activated microglial cells of the zona penumbra in the
middle cerebral artery occlusion (MCAO) model. The
microglial upregulation of P2X7 receptors in response to
oxygen deprivation has also been documented in the retinal
microglia [83]. However, the ischemia-induced upregula-
tion of P2X7 receptors appears in different cell types in a
temporally distinct manner. In a more recent study, an early
(1 day after MCAO occlusion) upregulation of the P2X7
receptor protein was observed in microglial cells, and later
(4–7 days after MCAO occlusion), the receptor was also
overexpressed in neurons and astrocytes of the periinfarct
area in spontaneously hypertensive rats, as revealed by co-
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markers [81]. P2X7 receptor overexpression is also associ-
ated with microglial cells in other pathological models; e.g.,
P2X7 receptor immunoreactivity appears to be upregulated
around amyloid plaques in activated microglia and astro-
cytes in the Tg2576 transgenic mice having mutant amyloid
precursor protein (APP) [71].
Altogether, these data indicate that the expression of P2X7
receptors is strongly activity-dependent during pathological
situations. Nonetheless, whether the change in their expres-
sion pattern and functional responsiveness is a simple
adaptive change or plays a more active pathogenetic role,
warrants further investigation. It is also a largely open
question whether the final outcome of versatile actions
mediated by microglial P2X7 receptors is protective or
harmful. As an example, P2X7 receptor deficient mice show
increased susceptibility to experimental autoimmune enceph-
alomyelitis (EAE), an animal model of sclerosis multiplex
[84], which is potentially due to the decreased microglial
secretion of the protective endocannabinoid 2-AG [72]. On
the other hand, chronic inflammatory and neuropathic pain is
almost completely abolished in the same mice line, which is
attributed partly to disrupted microglial production of the
inflammatory cytokine IL–1β [68]. Here we have to mention
than in addition to those present on the surface of microglial
cells, P2X7 receptors on other cell types (i.e., on astroglia
and neurons) may also contribute to disease pathology.
In addition to P2X7 receptors, other subtypes of the P2
receptor family, responding to lower concentration of ATP,
are also involved in different aspects of microglial
activation [85]. Thus, microglial Ca
2+ influx could be also
initiated by lower agonist concentrations, effects, which are
associated to a non-P2X7 ionotropic, probably P2X4
receptor activation, and there is also a metabotropic, P2Y
receptor mediated response [59, 85]. The expression of
P2X4 receptors is enhanced in the spinal cord microglia
after peripheral nerve injury [86, 87], and this receptor and
the subsequent activation of the p38 MAP kinase pathway,
have been shown to be involved in the generation of
inflammatory and neuropathic pain [88, 89].
Early studies showed that exposure of microglial cells to
ATP leads to the accumulation of immediate early gene
products, c-fos, c-jun, junB and TIS11, effects most likely
mediated by P2Y receptor activation [90]. P2Y1 receptors
mediate the inhibition of the LPS induced IL-1β, and TNF-
α production [91]. The level of proinflammatory cytokines
therefore seems to be differentially and oppositely regulated
by ionotropic and metabotropic P2 receptors. The produc-
tion of the anti-inflammatory cytokine IL–6 upon LPS
challenge is inhibited by P2Y receptors [91], although the
involvement of pertussin toxin insensitive P2Y receptors in
the induction of IL–6 production has also been reported
[66]. In addition, stimulation of a Gi protein coupled,
P2Y12-like receptor induces membrane ruffling and che-
motaxis in cultured primary microglia [92]. Finally, a recent
study showed that the activation of P2Y but not P2X
receptors induces cyclooxigenase-2 (COX-2) expression in
the human microglia [93].
In contrast to the plethora of experimental data obtained
in glial cells kept in culture, much less data have been
accumulated on the role of glial P2 receptors in more
integrated systems, where the cell architecture and extra-
cellular environment are retained. Nonselective cationic
membrane currents could be recorded from identified
resting microglial cells in acute brain slices in response to
ATP (1 mM) and BzATP (0.2 mM) application, which
presumably reflects the activation of P2X7 receptors,
although the underlying receptor subtype has not been
identified pharmacologically [94]. BzATP also activates
microglial P2X7 receptors in the isolated rat inner retina,
which leads to the permeabilization of this cell type [95].
Moreover, intrastriatal administration of ATP promotes cell
death in the striatum in vivo, which extends to both
neurons, astrocytes and microglial cells, as confirmed by
immunostaining by cell-type specific markers NeuN, glial
fibrillary acidic protein (GFAP) and OX-42, respectively
[96]. However, this effect was mimicked by α,β-methy-
lene-ATP and ATPγS, and antagonized by reactive blue 2,
but not by pyridoxal-phosphate-6-azophenyl-2′,4′-disul-
phonic acid (PPADS), and therefore is mediated by an
unidentified subtype of P2 receptors.
Modulation of microglial activation by adenosine
receptors
Although relatively limited data have been accumulated on
the adenosinergic modulation, microglial cells undoubtedly
express functional A1,A 2A and A3 but not A2B adenosine
receptors [97], which regulate different aspects of the
microglial response [98].
The pivotal role of A1 adenosine receptors in neuro-
inflammation is underscored by a recent study showing that
A1 receptor null mice develop a severe form of experimen-
tal autoimmune encephalomyelitis (EAE), which indicates
that endogenous adenosine might have a protective role in
the defense against this disease [99]. The involvement of
endogenous adenosine in the development of the disease is
supported by the downregulation of A1 adenosine receptors
in microglia of A
þ=þ
1 mice and by the beneficial effect of
caffeine, which upregulates A1 receptors and reduces
disease severity concomitantly [99]. Although the identifi-
cation of cellular effects underlying the protective action of
endogenous adenosine awaits further investigation, these
findings offer a novel opportunity for the treatment of
sclerosis multiplex and other neuroinflammatory diseases.
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regulates the transcription and the de novo synthesis of
various subtypes of K
+ channels, via cAMP- and PKC-
mediated pathways in cultured rat microglial cells; whereas
the expression of Kv1.3 type K
+ channels are enhanced at
both the mRNA and the protein level, only the mRNA but
not the protein synthesis of ROMK1 channels seems to be
regulated by A2A receptors [100]. This mechanism could
participate in the transition of the microglia from the resting
state to the activated form, in which the function of K
+
channels seems to play a pivotal role [47]. The A2A
receptor agonist CGS21680 also increases the mRNA
expression of nerve growth factor (NGF) and promotes
t h er e l e a s eo ft h eN G Fp r o t e i n[ 101]a saw e l la s
upregulates COX-2 and induces subsequent PGE2 release
in rat microglia again by interacting with A2A receptors and
downstream activation of the cAMP pathway [97].
Selective stimulation of A3 adenosine receptors induces
p38 and ERK1/2 phosphorylation in primary murine
microglia and in the N13 microglial cell line [102, 103].
This effect is mediated by Gi protein coupling and the
phosphatidylinositol-3′-kinase (PI3K) [103], and is absent
in microglial cells derived from A3 receptor deficient
transgenic mice [102].
Adenosinergic stimulation also influences the prolifera-
tion/survival of microglial cells; however, the clear-cut
identity of the underlying receptor subtype involved in
these effects is still uncertain. Thus, early studies indicate
that only the simultaneous activation of A1 and A2A
receptors could promote microglia proliferation, but this
action can be prevented by the A1 selective antagonist
DPCPX [104]. On the other hand, the adenosine receptor
agonist 2-chloroadenosine also induces apoptosis in rat
microglial cells; however, the identity of the adenosine
receptor responsible for this latter effect remains unknown
[105].
Conclusions
It is now increasingly clear that ATP is one of the key
players of microglial activation, which regulates numerous
elements of microglial response from membrane potential
to long-lasting transcriptional changes and also affects cell
survival. Nevertheless, there are a number of aspects which
need further investigation. Despite of the wealth of data on
ATP mediated signaling obtained in cultured microglia, the
present knowledge is poorly extrapolated to in vivo and
disease conditions. The pathways of endogenous activation
of purine receptors during the microglial response also need
to be better explored. Finally, the mechanisms underlying
the protective action of adenosine in the process of
microglial activation awaits further investigation. The
progress along this line is essential for the therapeutic
utilization of purinergic signaling system in neurodegener-
ative diseases.
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